DocumentsDate added
Original article
Satwant Kaur1,*, Harjinder Singh2, Kumud Bala Gupta3, Anupa Sood4, Swaran Kaur5
Affiliation:
1Associate Professor, M.M. Medical College & Hospital, Kumarhatti Solon(HP),India
2Assistant Professor, M.M. Medical College & Hospital, Kumarhatti Solon(HP),India
3Professor & Head Department of OBG Department, M.M. Medical College & Hospital, Kumarhatti Solon(HP),India
4Professor, M.M. Medical College & Hospital, Kumarhatti Solon(HP),India
5Professor & Head of Pathology Department in BPSGMC Khanpur-Sonepat(Haryana),India
The name of the department(s) and institution(s) to which the work should be attributed:
1.M.M. Medical College & Hospital, Kumarhatti Solon(HP),India
2.BPSGMC Khanpur-Sonepat (Haryana),India
Address reprint requests to
* Dr Satwant Kaur
Flat no. 228/J Spangle Condos, Dhakoli SAS Nagar Mohali, Punjab: 160104
Article citation: Kaur S, Singh H, Gupta KB, Sood A, Kaur S. Diagnosis of chronic pelvic pain (CPP):USG V/S DL. J Pharm Biomed Sci. 2015; 05(06):516-518. Available at www.jpbms.info
ABSTRACT:
Objective: To find out the correlation between two modalities i.e. USG and DL used in diagnosis of chronic pelvic pain.
Method: One hundred women with chronic pelvic pain attending Gynae OPD were included. They were examined clinically and subjected to USG and DL.
Results: Among the 78 patients with abnormal findings on laparoscopy only 45 had positive USG findings. Though USG had a higher sensitivity for ovarian cysts, laparoscopy was more predictive for other positive findings.
Conclusion: Diagnostic laparoscopy is more sensitive method for diagnosis of chronic pelvic pain.
KEYWORDS: Pelvic Pain; Laparoscopy; Ultrasonography; Chronic pelvic pain; USG; Gynaecological.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Majority of the information gathered are from media sources which don’t reflect the author’s own opinion.
Copyright © 2015 Kaur S, Singh H, Gupta KB, Sood A, Kaur S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report
Tanima Bose, PhD*
Affiliation:
Leibniz Institute for Neurobiology, Brenneckestrasse 6, D-39118 Magdeburg, Germany
The name of the department(s) and institution(s) to which the work should be attributed:
Leibniz Institute for Neurobiology, Brenneckestrasse 6, D-39118 Magdeburg, Germany
Address reprint requests to
Tanima Bose, PhD
Leibniz Institute for Neurobiology,
Brenneckestrasse 6, D-39118 Magdeburg, Germany
Article citation: Bose T. Azathiorpine-induced Idiosyncratic Liver-injury. J Pharm Biomed Sci. 2015; 05(06):449-452. Available at www.jpbms.info
ABSTRACT:
Autoimmune hepatitis is a rare autoimmune disorder. The regular treatments for this disease is the administration of regular immunosuppressants like Azathiorpine, Metabolic Mycophenolic Acid in addition to steroids. The adverse effects of these immunosuppressants are poorly described in the literature. Here is the description of one case report where the patient had maximum level of severity of autoimmune hepatitis within weeks of exposure to Azathiorpine.
KEYWORDS: Autoimmune hepatitis; Azathiorpine.
ACKNOWLEDGEMENT
I would like to acknowledge Dr. Subhra Mandal, Nijmegen, Netherlands for her continuing support in writing this Case Report. There is no source of funding for this work. There is no financial conflict with the subject matter discussed in the manuscript.
REFERENCES
1.Watanabe A, Hobara N, Tobe K, Endo H, Nagashima H. Biochemical and morphological study on hepatotoxicity of azathioprine in rat. Acta medica Okayama 1979, 33(1): 5-14.
2.Okan G, Vural P, Peker O, Colakoglu E, Saruc M. Azathioprine-induced liver injury in a patient with multiple autoimmune syndrome. The Journal of dermatological treatment 2010, 21(6): 357-360.
3.Du Vivier A, Munro DD, Verbov J. Treatment of psoriasis with azathioprine. British medical journal 1974, 1(5897): 49-51.
4.Harvey C, Dixon JS, Bird HA. Serum IgA concentration and hepatotoxicity in rheumatoid arthritis treated with azathioprine. Br Med J (Clin Res Ed) 1983, 287(6391): 534.
5.Blogowski W, Marlicz W, Smereczynski A, Lawniczak M, Lewosiuk A, Starzynska T. Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacology and immunotoxicology 2011, 33(2): 398-402.
6.Lopez-Martin C, Chaparro M, Espinosa L, Bejerano A, Mate J, Gisbert JP. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. Gastroenterologia y hepatologia 2011, 34(6): 385-392.
7.Ware AJ, Luby JP, Hollinger B, Eigenbrodt EH, Cuthbert JA, Atkins CR, et al. Etiology of liver disease in renal-transplant patients. Annals of internal medicine 1979, 91(3): 364-371.
8.Ramalho HJ, Terra EG, Cartapatti E, Barberato JB, Alves VA, Gayotto LC, et al. Hepatotoxicity of azathioprine in renal transplant recipients. Transplantation proceedings 1989, 21(1 Pt 2): 1716-1717.
9.Lemarchand P, Desrumeaux B, Bercoff E, Manchon ND, Chassagne P, Deshayes P, et al.Cholestasis and sinusoidal dilatation following treatment with azathioprine. Gastroenterologie clinique et biologique 1986, 10(12): 853-854.
10.Barrowman JA, Kutty PK, Ra MU, Huang SN. Sclerosing hepatitis and azathioprine. Digestive diseases and sciences 1986, 31(2): 221-222.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Bose T. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original Research
Renu Nagar*
Affiliation:
Head of Biochemistry & Point of care in a SEHA Hospital, Abu Dhabi, UAE
The name of the department(s) and institution(s) to which the work should be attributed:
SEHA Hospital, Abu Dhabi, UAE
Address reprint requests to
* Dr Renu Nagar
dr.renunagar@yahoo.com
Article citation: Nagar R. Delivering quicker reports for laboratory tests ordered in emergency departments. J Pharm Biomed Sci. 2015;05(06):505-515. Available at www.jpbms.info
ABSTRACT:
Prolonged turnaround time (TAT) of STAT emergency samples is the single most common cause of complaints about laboratory services all over the world. While the clinicians understandably desire quicker results for quicker clinical decisions affecting clinical outcomes, course and cost of treatment of these very sick patients; pathologists are frustrated by the unrealistic expectations of clinicians, excessive load of unnecessary STAT orders and delays outside laboratories affecting their TAT. This study was planned to find ways to improve TAT of emergency samples with the aim of quicker diagnosis, shorter stay in emergency, improved efficiencies of Emergency department (ED) and Laboratory (Lab), reducing hospital costs and improving patient experience. It was found that causes for delays most often lay outside lab. The remedy lay in correcting certain practices such as leaving drawn samples on bedside before transportation, drawing samples long after logging in Hospital information system, snags in Pnuematic tube system and delayed answering of lab calls in ED informing about critical results. Unnecessary ordering of tests as STAT increased the work load in lab. Other unexpected reasons for prolonged TAT were: non-cancellation of orders for rejected samples but waiting for arrival of a redrawn sample; and placing of future STAT orders for patients admitted from Emergency department. While the former resulted in prolonged Lab time, the latter resulted in prolonged Sample draw time and transport time as the hospital uses Pneumatic tube system for ED samples, but courier system for wards samples.
KEYWORDS: Emergency department (ED); Critical test; STAT tests; Critical result; Turnaround time (TAT); Length of stay; SWOT analysis; Root cause analysis; Fish bone diagram; Process mapping, PDCA; Efficiency of ED; Lab efficiency.
REFERENCES
1.Dimeski G, Silvester B, Ungerer J, Johnson L and Martin JH. Policy change to improve pathology turnaround time and reduce costs–possible to do both? Biochem Med. 2013; 23(3): 296–302.
2.Bradley V. Placing emergency department crowding on the decision agenda. Nurs Econ. 2005;23:14–24.
3.Goswami B, Singh B, Chawla R, Gupta VK, and Mallika V. Turn Around Time (TAT) as a Benchmark of Laboratory Performance. Indian J Clin Biochem. 2010; 25(4): 376–379.
4.HawkinsRC. Laboratory Turnaround Time. Clin Biochem Rev. 2007; 28(4): 179–194.
5.Watts NB. Reproducibility (precision) in alternate site testing. A clinician’s perspective. Arch Pathol Lab Med. 1995;119:914–7.
6.Neuberger J, Peters M. The clinical interface - a British physician’s view. Clin Chim Acta. 1996;248:11–8.
7.Handorf CR. College of American Pathologists Conference XXVIII on alternate site testing: introduction. Arch Pathol Lab Med. 1995;119:867–73.
8.Steindel SJ, Howanitz PJ. Physician satisfaction and emergency department laboratory test turnaround time. Arch Pathol Lab Med. 2001;125:863–71.
9.Hilborne LH, Oye RK, McArdle JE, Repinski JA, Rodgerson DO. Evaluation of stat and routine turnaround times as a component of laboratory quality. Am J Clin Pathol. 1989;91:331–5.
10.Steindel SJ, Howanitz PJ. Changes in emergency department turnaround time performance from 1990 to 1993. A comparison of two College of American Pathologists Q-probes studies. Arch Pathol Lab Med. 1997;121:1031–41.
11.Howanitz JH, Howanitz PJ. Timeliness as a quality attribute and strategy. Am J Clin Pathol. 2001;116:311–315.
12.Manor PG. Turnaround times in the laboratory: a review of the literature. Clin Lab Sci. 1999;12:85–89.
13.Lundberg GD. Acting on significant laboratory results. JAMA. 1981;245:1762–3.
14.Crook MA. Near patient testing and pathology in the new millennium. J Clin Pathol. 2000;53:27–30.
15.Fermann GJ and Suyama J. Point of care testing in the emergency department. J Emerg Med. 2002;22:393–404
16.Seamonds B. Medical, economic, and regulatory factors affecting point-of-care testing. A report of the conference on factors affecting point-of-care testing, Philadelphia, PA 6–7. 1994. Clin Chim Acta. 1996;249:1–19.
17.Hicks JM, Haeckel R, Price CP, Lewandrowski K and Wu AH. Recommendations and opinions for the use of point-of-care testing for hospitals and primary care: summary of a 1999 symposium. Clin Chim Acta. 2001;303:1–17.
18.Saxena S and Wong ET. Does the emergency department need a dedicated stat laboratory? Continuous quality improvement as a management tool for the clinical laboratory. Am J Clin Pathol. 1993;100:606–10
19.Manor PG. Turnaround times in the laboratory: a review of the literature. Clin Lab Sci. 1999;12:85–9.
20.Rollo JL and Fauser BA. Computers in total quality management. Statistical process control to expedite stats. Arch Pathol Lab Med. 1993;117:900–5.
21.Valenstein P. Turnaround time. Can we satisfy clinicians’ demands for faster service? Should we try? Am J Clin Pathol. 1989;92:705–6.
22.Truchaud A, Le Neel T, Brochard H, Malvaux S, Moyon M and Cazaubiel M. New tools for laboratory design and management. Clin Chem. 1997;43:1709–15.
23.Howanitz PJ, Cembrowski GS, Steindel SJ, Long TA. Physician goals and laboratory test turnaround times. A College of American Pathologists Q-Probes study of 2763 clinicians and 722 institutions. Arch Pathol Lab Med. 1993;117:22–8.
24.Valenstein PN and Emancipator K. Sensitivity, specificity, and reproducibility of four measures of laboratory turnaround time. Am J Clin Pathol. 1989;91:452–7.
25.Fattal GA, Tanasijevic MJ and Winkelman JW. Evolution beyond the shared services model of consolidated hospital clinical laboratories. Arch Pathol Lab Med. 1995;119:701–5.
26.Jones BA, Walsh MK and Ruby SG. Hospital nursing satisfaction with clinical laboratory services: a College of American Pathologists Q-Probes study of 162 institutions. Arch Pathol Lab Med. 2006;130:1756–61.
27.Khan K. Root Cause Analysis (RCA) of Prolonged Laboratory Turnaround Time in a Tertiary Care Set up. J Clin Diagn Res. Apr 2014; 8(4): FC05–FC08.
28.Ammenwerth E, Ehlers F, Eichstädter R, Haux R, Pohl U and Resch F. Systems analysis in health care: framework and example. Methods Inf Med. 2002;41:134–40.
29.Lenz R, Buessecker F, Herlofsen H, Hinrichs F, Zeiler T and Kuhn KA. Demand driven Evolution of IT Systems in Healthcare. Methods Inf Med. 2005;44:4–10.
Statement of Originality of work: The manuscript has been read and approved by the author, the requirements for authorship have been met, and that author believes that the manuscript represents honest and original work.
Source of funding: None
Competing interest / Conflict of interest: The author has no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the author and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Nagar R. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
D.DalyaThamer Ahmad*
Affiliation:
College of medicine, Al – Iraqia University, Adhamiyah, Baghdad, Iraq
The name of the department(s) and institution(s) to which the work should be attributed:
College of medicine, Al – Iraqia University, Adhamiyah, Baghdad, Iraq
Address reprint requests to
Dr.D.DalyaThamer Ahmad
College of medicine, Al–Iraqia University, Adhamiyah, Baghdad, Iraq
Article citation: Ahmad DT. Placental dysfunction disorders after prior miscarriages in a sample of Iraqi womens. J Pharm Biomed Sci. 2015; 05(06):440-448. Available at www.jpbms.info
ABSTRACT:
Objective: The aim of this study was to investigate the association between prior miscarriages and the risks of placental dysfunction disorders, including preeclampsia, stillbirth, birth of a small for gestational age (SGA) infant, placental abruption, and spontaneous preterm birth.
Study Design: In a population-based cohort study including 72 primiparous women, we estimated risks of placental dysfunction disorders for women with 1(n = 24 ), 2 (n = 20 ) and 3 or more (n = 18 ) self-reported prior miscarriages. Risks were calculated as odds ratios by unconditional logistic regression analysis and adjustments were made for maternal age, early pregnancy body mass index, smoking habits, years of formal education, in vitro fertilization, chronic hypertension, pregestational diabetes, hypothyroidism, systemic lupus erythematosis and fetal sex .
Results: Compared with women with no prior miscarriage, women with 1 prior miscarriage had almost no increased risks. Women with 2 prior miscarriages had increased risks of spontaneous preterm birth, preterm (<37 weeks) SGA infant, and placental abruption. The rates of all disorders were higher for women with 3 or more prior miscarriages compared with women without prior miscarriages: preeclampsia, 50% vs 30%; stillbirth, 22.22 % vs 0%, SGA infant, 22.22 % vs 10 %, placental abruption, 27.78 % vs 10 %; and spontaneous preterm birth, 27.78 % vs 10 %. The adjusted odds ratios for preterm (<37 weeks) disorders in women with 3 prior miscarriages were approximately 3.4, neonatal death, 11.11 % vs 0%.
Conclusion: History of 2 or more miscarriages is associated with an increased risk of placental dysfunction disorders and should be regarded as a risk factor in antenatal care
KEYWORDS: Intrauterine growth restriction; miscarriage; placental abruption; preeclampsia, spontaneous preterm birth; stillbirth.
REFERENCES
1.Julia Shelley. Miscarriage and time to next pregnancy : British Medical Journal 2010;341:c4181.
2.Eleanor R Love, Siladitya Bhattacharya, Norman C Smith, Sohinee Bhattacharya. Research Effect of interpregnancy interval on outcomes of pregnancy after miscarriage: retrospective analysis of hospital episode statistics in Scotland.BMJBritish Medical Journal, 2010;341:c3967.
3.Brosens, I., Pijnenborg, R., Vercruysse, L., and Romero, R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011; 204: 193–201.
4.Jivraj, S., Anstie, B., Cheong, Y.C., Fairlie, F.M., Laird, S.M., and Li, T.C. Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study. Hum Reprod. 2001; 16: 102–106.
5.Weintraub, A.Y., Sergienko, R., Harlev, A. et al. An initial miscarriage is associated with adverse pregnancy outcomes in the following pregnancy. Am J Obstet Gynecol. 2011; 205: 286.E1–286.E5.
6.Sheiner, E., Levy, A., Katz, M., and Mazor, M. Pregnancy outcome following recurrent spontaneous abortions. Eur J ObstetGynecolReprod Biol. 2005; 118: 61–65.
7. Oliver-Williams C, Fleming M, Wood AM, Smith GCS. Previous miscarriage and the subsequent risk of preterm birth in Scotland, 1980–2008: a historical cohort study. BJOG 2015; DOI: 10.1111/1471-0528.13276.
8.Buchmayer, S.M., Sparén, P., and Cnattingius, S. Previous pregnancy loss: risks related to severity of preterm delivery. Am J Obstet Gynecol. 2004; 191: 1225–1231.
9.Cara Bicking Kinsey, Kesha Baptiste-Roberts, Junjia Zhu, Kristen H. Kjerulff .Effect of Previous Miscarriage on the Maternal Birth Experience in the First Baby Study.JOGNN . Journal of Obstetric, Gynecologic, & Neonatal Nursing . 2013; 42: 4: 442–450.
10.Rasmussen, S. and Irgens, L.M. History of fetal growth restriction is more strongly associated with severe rather than milder pregnancy-induced hypertension. Hypertension. 2008; 51: 1231–1238.
11.Wikstrom, A.K., Stephansson, O., and Cnattingius, S. Previous preeclampsia and risks of adverse outcomes in subsequent nonpreeclamptic pregnancies. Am J Obstet Gynecol. 2011; 204: 148.e1–148.e6.
12.Kulandavelu, S., Whiteley, K.J., Bainbridge, S.A., Qu, D., and Adamson, S.L. Endothelial NO synthase augments fetoplacental blood flow, placental vascularization, and fetal growth in mice. Hypertension. 2013; 61: 259–266.
13.Espinoza, J., Uckele, J.E., Starr, R.A., Seubert, D.E., Espinoza, A.F., and Berry, S.M. Angiogenic imbalance: the obstetric perspective. Am J Obstet Gynecol. 2010; 203: 17.e1–17.e8.
14.Torry, D.S., Leavenworth, J., Chang, M. et al. Angiogenesis in implantation. J Assist Reprod Genet. 2007; 24: 303–315.
15.Rabbani, M.L. and Rogers, P.A. Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats. Reproduction. 2001; 122: 85–90.
16.Plaisier, M. Decidualisation and angiogenesis. Best Pract Res ClinObstetGynaecol. 2011; 25: 259–271.
17.Plaisier, M., Dennert, I., Rost, E., Koolwijk, P., van Hinsbergh, V.W., and Helmerhorst, F.M. Decidual vascularization and the expression of angiogenic growth factors and proteases in first trimester spontaneous abortions. Hum Reprod. 2009; 24: 185–197. 18.Jauniaux, E., Hempstock, J., Greenwold, N., and Burton, G.J. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancies. Am J Pathol. 2003; 162: 115–125.
19.Su, M.T., Lin, S.H., and Chen, Y.C. Genetic association studies of angiogenesis- and vasoconstriction-related genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod Update.2011; 17: 803–812
20.Galazios, G., Papazoglou, D., Tsikouras, P., and Kolios, G. Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonat. 2009; 22: 371–378.
21.Bhattacharya, S., Townend, J., Shetty, A., and Campbell, D. Does miscarriage in an initial pregnancy lead to adverse obstetric and perinatal outcomes in the next continuing pregnancy?.BJOG. 2008; 115: 1623–1629.
22.Basso, O., Olsen, J., and Christensen, K. Risk of preterm delivery, low birthweight and growth retardation following spontaneous abortion: a registry-based study in Denmark. Int J Epidemiol. 1998; 27: 642–646.
23.Trogstad, L., Magnus, P., Skjaerven, R., and Stoltenberg, C. Previous abortions and risk of pre-eclampsia.Int J Epidemiol. 2008; 37: 1333–1340.
24.El-Bastawissi AY, Sorensen TK, Akafomo CK, Frederick IO, Xiao R, Williams MA. History of fetal loss and other adverse pregnancy outcomes in relation to subsequent risk of preterm delivery.Matern Child Health J. 2003 Mar;7(1):53-8.
25.Hammoud AO, Merhi ZO, Diamond M, Baumann P. Recurrent pregnancy loss and obstetric outcome. Int J GyneacolObstet 2007;96:28-29.
26.McCarthy FP1, Khashan AS, North RA, Rahma MB, Walker JJ, Baker PN, Dekker G, Poston L, McCowan LM, O'Donoghue K, Kenny LC. Pregnancy loss managed by cervical dilatation and curettage increases the risk of spontaneous preterm birth. Humrep 2013 Dec;28(12):3:197-206.
27. R.H.F. van Oppenraaij, E. Jauniaux, O.B. Christiansen, J.A. Horcajadas, R.G. Farquharson and N. Exalto1,6 on behalf of the ESHRE Special Interest Group for Early Pregnancy (SIGEP). Predicting adverse obstetric outcome after early pregnancy events and complications. Oxford Journals2009 ;15; 4: 409-421.
28.Lang JM, Lieberman E, Cohen A. A comparison of risk-factors for preterm labor and term small-for-gestational-age birth. Epidemiology 1996;7:369-376.
29.Voigt M1, Olbertz D, Fusch C, Krafczyk D, Briese V, Schneider KT . The influence of previous pregnancy terminations, miscarriages and still-births on the incidence of babies with low birth weight and premature births as well as a somatic classification of newborns . Z GeburtshilfeNeonatol [Article in German]. 2008 Feb;212(1):5-12.
30.Moreau C, Kaminski M, Ancel PY, Bouyer J, Escande B, Thiriez G, Boulot P, Fresson J, Arnaud C, Subtil D, et al.; EPIPAGE Group. Previous induced abortions and the risk of very preterm delivery: results of the EPIPAGE study. Br J ObstetGynaecol 2005;112:430-437.
31.Raatikainen K, Heiskanen N, Heinonen S. Induced abortion: not an indepedent risk factor for pregnancy outcome, but a challenge for health counselling. Ann Epidemiol 2006;16:587-592.
32.Parazzini F, Cipriani S, Chiaffarino F, Sandretti F, Bortolus R, Chiantera V. Induced abortion and risk of small-for-gestational-age birth. Br J ObstetGynaecol 2007;114:1414-1418.
33.Reime B, Schücking BA, Wenzlaff P. Reproductive outcomes in adolescents who had a previous birth or an induced abortion compared to adolescents’ first pregnancies. BMC Pregnancy Childbirth 2008;31:4.
Source of funding: None
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Ahmad DT. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Kawkab Abdulla Al-Saadi1,*, Hassan Fadhil Naji2, Ali Hmood Al-Saadi2,
Adnan Hashim Muhammed Ali3
Affiliation:
1University of Karbala, College of Sciences, Department of Biology, Iraq
2University of Babylon, College of Sciences, Department of Biology, Iraq
3Al-Hussein hospital, Ear Nose Throat (ENT) unit, Iraq
The name of the department(s) and institution(s) to which the work should be attributed:
1. University of Karbala, College of Sciences, Department of Biology, Iraq
2. University of Babylon, College of Sciences, Department of Biology, Iraq
3. Al-Hussein hospital, Ear Nose Throat (ENT) unit, Iraq
Address reprint requests to
*Kawkab Abdulla Al-Saadi.
University of Karbala, College of Sciences, Department of biology, Iraq
Article citation: Al-Saadi KA, Naji HS, Al-Saadi AH, Muhammed Ali AH. Detection and identification of Streptococcus pyrogenes es from ENT patients by different methods. J Pharm Biomed Sci. 2015; 05(06):480-486. Available at www.jpbms.info
ABSTRACT:
Streptococcus pyogenes (S. pyogenes ) is a Gram-positive bacterium tainting the upper respiratory tract, such as the tonsils and pharynx, and it also induces post-infection diseases such as rheumatic fever and glomerulonephritis. The study aim was to compare between different methods for detection and identification of S. pyogenes from Ear, nose and throat (ENT) patients. A total of 10 (ten) S. pyogenes strains were analyzed, these were recovered from throat cultures of 150 patients with (ENT). Identification of bacteria carry out depending on the conventional biochemical tests, Strepto System 9R, using universal PCR primer, followed by RFLP, and finally amplification of the specific genes which included spy 1258 and dnase B. The molecular methods shows, that all S. pyogenes isolates contains dnase B and Spy 1258 genes and found to be absent in the non pyogenic streptococci.
KEYWORDS: PCR; Group A Streptococcus; RFLP; dnaseB; spy1258; 16S rRNA.
References:
1.Bernish, B., and van de Rijn, I. Characterization of a two-component system in Streptococcus pyogenes which is involved in regulation of hyaluronic acid production. Journal of Biological Chemistry 1999;274(8):4786-4793. [Original source]
2.Bisno, A., and Stevens, D. Streptococcus pyogenes ( Including streptococcal toxic shock syndrome and necrotizing fasciitis). Principles and practice of infectious diseases 2000;2:2101-2117.
3.Bruneau, S., De Montclos, H., Drouet, E., and Denoyel, G. rRNA gene restriction patterns of Streptococcus pyogenes: epidemiological applications and relation to serotypes. Journal of clinical microbiology 1994; 32(12):2953-2958. [Pub Med]
4.Dunne, E. M., Marshall, J. L., Baker, C. A., Manning, J., Gonis, G., Danchin, M. H., Smeesters, P. R., Satzke, C., and Steer, A. C. Detection of group a streptococcal pharyngitis by quantitative PCR. BMC infectious diseases 2013;13(1):312. [Pub Med], [Pubmed Central]
5.Hasegawa, T., Minami, M., Okamoto, A., Tatsuno, I., Isaka, M., and Ohta, M. Characterization of a virulence-associated and cell-wall-located DNase of Streptococcus pyogenes. Microbiology 2010;156(1):184-190. [Pub Med]
6.Jenkins, C., Ling, C. L., Ciesielczuk, H. L., Lockwood, J., Hopkins, S., McHugh, T. D., Gillespie, S. H., and Kibbler, C. C. Detection and identification of bacteria in clinical samples by 16S rRNA gene sequencing: comparison of two different approaches in clinical practice. Journal of medical microbiology 2012; 61(Pt 4), 483-488. [Pub Med]
7.Kalghatgi, A., Praharaj, A., Sahni, A., Pradhan, D., Kumaravelu, S., Prasad, P., and Nagendra, A. Detection of bacterial pathogens in cerebrospinal fluid using restriction fragment length polymorphism. Medical Journal Armed Forces India 2008;64(1):29-32. [Original source]
8.Ley, B., Linton, C., Bennett, D., Jalal, H., Foot, A., and Millar, M. Detection of bacteraemia in patients with fever and neutropenia using 16S rRNA gene amplification by polymerase chain reaction. European Journal of Clinical Microbiology and Infectious Diseases 1998;17(4):247-253. [Pub Med]
9.Liu, D., Hollingshead, S., Swiatlo, E., Lawrence, M. L., and Austin, F. W. Rapid identification of Streptococcus pyogenes with PCR primers from a putative transcriptional regulator gene. Research in microbiology 2005;156(4):564-567. [Pub Med], [CrossRef],[CAS], [Web of Science®]
10.Lu, J.-J., Perng, C.-L., Lee, S.-Y., and Wan, C.C. Use of PCR with universal primers and restriction endonuclease digestions for detection and identification of common bacterial pathogens in cerebrospinal fluid. Journal of clinical microbiology 2000;38(6):2076-2080.[Pub Med], [Pub Medcentral]
11.Maslow, J. N., Mulligan, M. E., and Arbeit, R. D. Molecular epidemiology: application of contemporary techniques to the typing of microorganisms. Clinical Infectious Diseases 1993;153-162. [Pub Med]
12.McCabe, KM., Khan, G., Zhang, Y.-H., Mason, E. O., and McCabe, E. R. Amplification of bacterial DNA using highly conserved sequences: automated analysis and potential for molecular triage of sepsis. Pediatrics 1995; 95(2):165-169. [Pub Med]
13.Meisal, R., Andreasson, I. K., Høiby, E. A., Aaberge, I. S., Michaelsen, T. E., and Caugant, D. A. Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: emm types, multilocus sequence types, and superantigen profiles. Journal of clinical microbiology 2010;48(3):842-851. [Pub Med]
14.Nandi, S., Ganguly, N. K., Kumar, R., Bakshi, D. K., Sagar, V., and Chakraborti, A. Genotyping of group A streptococcus by various molecular methods. Indian Journal of Medical Research 2008;127(1):71. [Pub Med]
15.Nilsson, W. B., Paranjype, R. N., DePaola, A., and Strom, M. S. Sequence polymorphism of the 16S rRNA gene of Vibrio vulnificus is a possible indicator of strain virulence. Journal of clinical microbiology 2003;41(1):442-446. [Pub Med]
16.Olsen, G. J., and Woese, C. R. (1993). Ribosomal RNA: a key to phylogeny. The FASEB journal 1993;7(1):113-123. [Pub Med]
17.Rahmani, S., Forozandeh, M., Mosavi, M., and Rezaee, A. Detection of bacteria by amplifying the 16S rRNA gene with universal primers and RFLP. Medical Journal of The Islamic Republic of Iran (MJIRI) 2006;19(4): 333-338. [Original source]
18.Sauer, P., Gallo, J., Kesselová, M., Kolar, M., and Koukalová, D. Universal primers for detection of common bacterial pathogens causing prosthetic joint infection. BIOMEDICAL PAPERS-PALACKY UNIVERSITY IN OLOMOUC 2005;149(2):285-288. [Original source]
19.Schabauer, L., Wenning, M., Huber, I., and Ehling-Schulz, M. Novel physico-chemical diagnostic tools for high throughput identification of bovine mastitis associated gram-positive, catalase-negative cocci. BMC veterinary research 2014;10(1):156. [BMC], [Cross ref]
20.Slinger, R., Goldfarb, D., Rajakumar, D., Moldovan, I., Barrowman, N., Tam, R., and Chan, F. Rapid PCR detection of group A streptococcus from flocked throat swabs: a retrospective clinical study. Ann Clin Microbiol Antimicrob 2011;10(1):33. [Pub Med]
21.Woo, P. C., Fung, A. M., Lau, S. K., Wong, S. S., and Yuen, K.Y. Group G beta-hemolytic streptococcal bacteraemia characterized by 16S ribosomal RNA gene sequencing. Journal of clinical microbiology 2001;39(9):3147-3155.[Pub Med]
22. Harris K. A., Hartley J. C. Development of broad-range 16S rDNA PCR for use in the routine diagnostic clinical microbiology service. J Med Microbiol 2003;52:685–691 10.1099/jmm.0.05213-0 [PubMed], [Cross Ref].
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Al-Saadi KA, Naji HS, Al-Saadi AH, Muhammed Ali AH. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.